SCHEMBL5652832

SCHEMBL5652832

COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)no4)cc3Cl)c2cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.65
PDGFRA P16234 16/20 0.65
FLT3 P36888 3/20 0.56
CYP3A4 P08684 1/20 0.55
RIPK2 O43353 1/20 0.53
STK10 O94804 1/20 0.53
ABL1 P00519 1/20 0.53
LCK P06239 1/20 0.53
LYN P07948 1/20 0.53
RET P07949 1/20 0.53
MET P08581 1/20 0.53
PDGFRB P09619 1/20 0.53
KIT P10721 1/20 0.53
BCR P11274 1/20 0.53
FGFR1 P11362 1/20 0.53
SRC P12931 1/20 0.53
FLT1 P17948 1/20 0.53
MAPK3 P27361 1/20 0.53
HTR2A P28223 1/20 0.53
MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653628 0.89 FLT3 (0.70) KDRPDGFRAFLT3MET
SCHEMBL5655643 0.88 KDR (0.61) KDRPDGFRAFLT3
SCHEMBL6380294 0.85 FLT3 (0.64) KDRPDGFRAFLT3MET
SCHEMBL5652592 0.84 PDGFRA (0.68) KDRPDGFRAFLT3RIPK2STK10
SCHEMBL5649290 0.83 KDR (0.77) KDRPDGFRAFLT3CYP3A4RIPK2
SCHEMBL4668526 0.81 PDGFRA (0.68) KDRPDGFRA
SCHEMBL1875372 0.80 KDR (0.67) KDRPDGFRAMET
SCHEMBL4668522 0.80 PDGFRA (0.64) KDRPDGFRAMET
SCHEMBL5825428 0.78 PDGFRA (0.59) KDRPDGFRAMETKIT
SCHEMBL5653905 0.78 KDR (0.74) KDRPDGFRAFLT3CYP3A4RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1652847-A1 Quinoline and quinazoline derivatives for the treatment of tumors KIRIN BEER KABUSHIKI KAISHA (JP) 2006-05-03 EP claimed
US-7211587-B2 Quinoline derivatives and quinazoline derivatives having azolyl group KIRIN BEER KABUSHIKI KAISHA (KR) 2007-05-01 US disclosed
EP-1652847-A1 Quinoline and quinazoline derivatives for the treatment of tumors KIRIN BEER KABUSHIKI KAISHA (JP) 2006-05-03 EP disclosed
EP-1382604-B1 QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE KIRIN BREWERY (JP) 2005-12-28 EP disclosed
US-6821987-B2 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, KIRIN BEER KABUSHIKI KAISHA (JP) 2004-11-23 US disclosed
US-20040229876-A1 Quinoline derivatives and quinazoline derivatives having azolyl group KIRIN BEER KABUSHIKI KAISHA (JP) 2004-11-18 US disclosed
EP-1382604-A1 QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-21 EP disclosed
US-20030087907-A1 Quinoline derivatives and quinazoline derivatives having azolyl group KIRIN BEER KABUSHIKI KAISHA (JP) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229876-A1 Quinoline derivatives and quinazoline derivatives having azolyl group NQO2, H1-5, NRAS KDR 3455/4885PDGFRA 4104/4885FLT3 83/4885
US-20030087907-A1 Quinoline derivatives and quinazoline derivatives having azolyl group NQO2, H1-5, NRAS KDR 3455/4885PDGFRA 4104/4885FLT3 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.